Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amphista Shows New Data for Efficacy and CNS Activity of Targeted Protein Degraders
Details : Amphista Therapeutics is developing an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader. It is being evaluated in preclinical studies for neurodegenerative diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Bristol Myers Squibb
Deal Size : $1,280.0 million
Deal Type : Collaboration
Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
Details : Under the collaboration, Amphista is responsible for the discovery and development of small molecule protein degraders using Eclipsys™, its next-generation TPD platform and BMS is granted a global exclusive license to the resulting degraders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $30.0 million
April 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Bristol Myers Squibb
Deal Size : $1,280.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Merck Group
Deal Size : $1,044.0 million
Deal Type : Collaboration
Details : Amphista and Merck will collaborate to leverage Amphista's proprietary Eclipsys™ TPD platform and generate small molecule protein degraders for an initial three targets in oncology and immunology indications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Merck Group
Deal Size : $1,044.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $1,280.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, companies will work collaboratively to discover and develop small molecule protein degraders. Bristol Myers Squibb will be granted a global license to the degraders developed and will be responsible for development and c...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $30.0 million
April 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $1,280.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Advent Life Sciences
Deal Size : $7.5 million
Deal Type : Series A Financing
Details : This international financing provides Amphista with a firm foundation to underpin a Series B round to progress its oncology pipeline to the clinic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 04, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Advent Life Sciences
Deal Size : $7.5 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amphista Therapeutics Appoints Leading Protein Degradation Pioneer, Ian Churcher as CSO
Details : Amphista believes that Ian Churcher's scientific leadership will be a tremendous addition to the Amphista team as it progresses its TPD pipeline to the clinic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable